NCT00373841

Brief Summary

The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis. The studies will compare genetic and biologic markers of samples to changes in symptoms. The ultimate goal is to predict if or when patients are likely to experience a rapid decline in lung function due to disease progression.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
50mo left

Started Oct 2005

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress83%
Oct 2005Jul 2030

Study Start

First participant enrolled

October 1, 2005

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

September 6, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 8, 2006

Completed
23.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2030

Last Updated

October 29, 2025

Status Verified

September 1, 2025

Enrollment Period

24.8 years

First QC Date

September 6, 2006

Last Update Submit

October 28, 2025

Conditions

Idiopathic Pulmonary Fibrosis

Keywords

LungFibrosisIdiopathicBiomarkersGenomicsLongitudinal

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients aged 18 and older who have been diagnosed with IPF and referred by a Simmons Center doctor.

You may qualify if:

  • Patients who are 18 or older
  • Diagnosis of Idiopathic Pulmonary Fibrosis
  • Treated at the Simmons Center

You may not qualify if:

  • Other Lung Illness

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Michelle F MacPherson

Pittsburgh, Pennsylvania, 15213, United States

RECRUITING

Related Publications (1)

  • Chien JW, Richards TJ, Gibson KF, Zhang Y, Lindell KO, Shao L, Lyman SK, Adamkewicz JI, Smith V, Kaminski N, O'Riordan T. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J. 2014 May;43(5):1430-8. doi: 10.1183/09031936.00141013. Epub 2013 Oct 31.

    PMID: 24177001DERIVED

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples necessary to analyze disease progression in patient with idiopathic pulmonary fibrosis over a long period of time.

MeSH Terms

Conditions

Idiopathic Pulmonary FibrosisFibrosis

Condition Hierarchy (Ancestors)

Pulmonary FibrosisLung Diseases, InterstitialLung DiseasesRespiratory Tract DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Kevin F Gibson, MD

    University of Pittsburgh - Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Michelle MacPherson, MAT

CONTACT

412-647-4537macphersonmj@upmc.edu

Michelle Meyers, BSN RN

CONTACT

412-692-2149meyersma@upmc.edu

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Medicine

Study Record Dates

First Submitted

September 6, 2006

First Posted

September 8, 2006

Study Start

October 1, 2005

Primary Completion (Estimated)

July 1, 2030

Study Completion (Estimated)

July 1, 2030

Last Updated

October 29, 2025

Record last verified: 2025-09

Locations

US(1)